CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2018 |
Jun. 30, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
| SUBLICENSE REVENUE |
$ 2,000
|
$ 0
|
$ 2,000
|
$ 0
|
| OPERATING EXPENSES: |
|
|
|
|
| Sublicense transaction costs |
254
|
0
|
254
|
0
|
| General and administrative |
84
|
102
|
313
|
215
|
| Research and development |
322
|
112
|
623
|
379
|
| Total operating expenses |
660
|
214
|
1,190
|
594
|
| Income (loss) after operating expenses |
1,340
|
(214)
|
810
|
(594)
|
| Interest and other income (expense), net |
(62)
|
6
|
(122)
|
(9)
|
| Income (loss) from operations before taxes |
1,278
|
(208)
|
688
|
(603)
|
| Income tax benefit |
0
|
2
|
3
|
10
|
| NET INCOME (LOSS) |
1,278
|
(206)
|
691
|
(593)
|
| Less: Net Income (Loss) attributable to the noncontrolling interest |
0
|
0
|
0
|
0
|
| Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders |
$ 1,278
|
$ (206)
|
$ 691
|
$ (593)
|
| Per Share Information: |
|
|
|
|
| Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders |
$ 0.02
|
$ (0.01)
|
$ 0.01
|
$ (0.01)
|
| Basic and diluted shares outstanding |
54,385
|
40,885
|
54,385
|
40,885
|